Home | Welcome to Contract Pharma   
Last Updated Sunday, February 1 2015

Print RSS Feed

Search Results for 'Financial Report: AstraZeneca'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published August 8, 2014
Integration of BMS assets offsets losses Read More »
By Gil Roth
Published February 6, 2014
Generics drive sales down, more layoffs planned Read More »
Published October 31, 2013
Revenues, earnings fall off patent cliff Read More »
Published August 1, 2013
Generic erosion impacts results Read More »
Published April 25, 2013
Seroquel IR loss pummels revenues Read More »
Published July 26, 2012
Loss of exclusivity for key brands wallops results Read More »
Published February 2, 2012
Loss of nearly $2 billion in 2011 from generic competition, 7,300 more layoffs to come Read More »
Published April 23, 2007
AstraZeneca 1Q Revenues: $7 billion (+13%) 1Q Earnings: $1.6 billion (+10%) Comments: Growth in the quarter was driven by combined sales of five key products: Nexium, Seroquel, Crestor, Arimidex and Symbicort, up 17% to $3.6 billion. R&am… Read More »
Corden Pharma
By Michael Quirmbach, Vice President, Global Sales & Marketing
CordenPharma is your full-service CMO partner in the Contract Development & Manufacturing of APIs, Drug Products and associated Packaging Services. With multiple cGMP facilities across Europe and the US, CordenPharma provides flexible outsourcing… Read More »
Quantifying the Value of Time
By Ben Locwin, Ph.D., Healthcare Science Advisors
Published September 8, 2014
Clinical attrition and quality-adjusted life years make for dissatisfied patients Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On